Statistics from Altmetric.com
Q In postmenopausal women, does raloxifene reduce the risks of coronary events and invasive breast cancer?
Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Internal medicine ★★★★★★☆ Cardiology ★★★★★★☆ Geriatrics ★★★★★★☆ Haematology ★★★★★★☆ Oncology ★★★★★★☆ Rheumatology ★★★★★★☆ Gynaecology ★★★★★★☆ Endocrine ★★★★★☆☆
randomised placebo controlled trial (Raloxifene Use for The Heart [RUTH] trial).
blinded (clinicians, participants, outcome assessors, laboratory staff, and sponsor).*
Follow up period:
median 5.6 years.
177 centres in 26 countries worldwide.
10 101 postmenopausal women ⩾55 years of age (mean 68 y) with or at increased risk of coronary heart disease. Exclusion criteria included recent myocardial infarction (MI) or revascularisation procedure; history of cancer, venous thromboembolism (VTE), heart failure, or chronic liver or renal disease; life expectancy <5 …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.